Amissa
Amissa Health, based in Charlotte, North Carolina, is a women's health technology company focused on improving perimenopause care through data-driven clinical decision support.
Profile
Turns menopause symptoms and wearable data into clinical documentation to improve care decisions.
Amissa Health, based in Charlotte, North Carolina, is a women's health technology company focused on improving perimenopause care through data-driven clinical decision support. Founded in the early 2020s, the company has developed a platform that combines patient-reported symptoms with wearable device data to create structured, longitudinal documentation for healthcare providers. Amissa's approach addresses a well-documented gap in menopause care, where only 15% of U.S. women receive a formal diagnosis despite 85% experiencing symptoms that impact daily life.
The company has secured NIH backing, including a grant supporting research with Washington University's DRIVES Project to predict Alzheimer's risk using Apple Watch biometrics. Amissa operates at the intersection of clinical care and research, offering tools for both providers and researchers to track menopause symptoms and related health metrics. Its mobile app, available on iOS and Android, integrates with wearable devices to capture real-time data, reducing reliance on patient recall during clinical visits. The company's financial trajectory includes undisclosed funding rounds, with Crunchbase noting a growth score of 86 and heat score of 77 as of 2026, suggesting steady market interest in its niche.
Who buys this
- Healthcare providers treating perimenopausal patients
- Academic researchers studying women's health and aging
- Hospital systems implementing menopause care programs
- Pharmaceutical companies conducting menopause-related clinical trials
Strengths and what to watch
Strengths
- NIH-backed research credentials with Washington University collaboration
- Proprietary integration of wearable data with clinical symptom tracking
- Addresses a documented $24 billion gap in menopause-related healthcare costs
Watch for
- Dependence on third-party wearable ecosystems (Apple Watch/Health)
- Regulatory scrutiny as a health data intermediary between patients and providers
- Limited public disclosure of commercial traction beyond research grants
Key Information
- Founded
- 2020
- Headquarters
- Charlotte, North Carolina
Frequently Asked Questions
What does Amissa Health do?
Amissa Health transforms menopause symptoms and wearable data into clinical documentation. Their platform helps healthcare providers make better care decisions by combining patient-reported symptoms with real-time wearable device metrics. Focused on perimenopause, it addresses gaps where 85% of women experience symptoms but only 15% get diagnosed.
How does Amissa use wearable data for menopause care?
Amissa integrates Apple Watch and other wearable biometrics with symptom tracking. This creates structured, longitudinal health records that reduce reliance on patient recall during clinical visits. Their NIH-backed research with Washington University also explores wearable data for predicting Alzheimer's risk in menopausal women.
Is Amissa's menopause technology clinically validated?
Yes, Amissa holds NIH grants and collaborates with Washington University's DRIVES Project. Their approach addresses documented gaps in menopause care, with research focused on clinical decision support. The company complies with PHS/NIH financial conflict of interest requirements for health technology developers.
What healthcare providers use Amissa's platform?
Amissa serves clinicians treating perimenopausal patients, hospital systems implementing menopause programs, and researchers studying women's health. Their tools help document symptoms more accurately than traditional methods. Pharmaceutical companies also use the platform for menopause-related clinical trials.
How does Amissa compare to other menopause apps?
Amissa stands out with NIH-backed research credentials and clinical documentation capabilities. Unlike basic symptom trackers, it integrates wearable data for provider-facing decision support. The platform addresses a $24 billion gap in menopause-related healthcare costs through structured data capture.
What funding has Amissa Health received?
Amissa has secured undisclosed funding rounds and NIH research grants. Crunchbase reports a growth score of 86/100 and heat score of 77/100 as of 2026, indicating steady market interest. Their financial trajectory supports ongoing women's health technology development.
Sources
- www.amissa.com — Company's core product offering and clinical focus
- www.amissa.com — NIH grant details and research partnerships
- www.crunchbase.com — Company location and growth metrics
- www.amissa.com — Regulatory compliance with PHS/NIH requirements